Publications
2024
Dilán-Pantojas IO, Boonchalermvichien T, Taneja SB, Li X, Chapin MR, Karcher S, Boyce RD. Broadening the capture of natural products mentioned in FAERS using fuzzy string-matching and a Siamese neural network. Sci Rep. 2024 Jan 13;14(1):1272. doi: 10.1038/s41598-023-51004-4. PMID: 38218987; PMCID: PMC10787736.
2023
Bansal S, Ladumor MK, Paine MF, Unadkat JD. A physiologically-based pharmacokinetic model for cannabidiol in healhty adults, hepatically-impaired adults, and children. Drug Metab Dispos, online ahead of print, 2023. https://doi.org/10.1124/dmd.122.001128
PMID: 36972999
Li X, Ndungu P, Taneja SB, Chapin MR, Egbert SB, Akenapalli K, Paine MF, Kane-Gill SL, Boyce RD. An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration adverse event reporting system from January 2004 through September 2021. Clin Transl Sci, online ahead of print, 2023. https://doi.org/10.1111/cts.13505.
PMID: 36861661
PMCID: PMC10150409
Liyanage M, Blaquera CL, Piscitelli J, Penzak SR, Nolin TD, Paine MF, Ma JD. Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults. Int J Clin Pharmacol Ther, online ahead of print, 2023. https://doi.org/10.5414/CP204380
PMID: 37042268
Taneja, SB, Callahan, TJ, Paine, MF, Kane-Gill, SL, Kilicoglu, H, Joachimiak, MP, Boyce, RD. Developing a knowledge graph for pharmacokinetic natural product-drug interactions. J Biomed Inform, 140:104341, 2023. https://doi.org/10.1016/j.jbi.2023.104341.
PMID: 36933632
PMCID: PMC10150409
Tanna RS, Nguyen JT, Hadi DL, Layton ME, White JR, Cech NB, Oberlies NH, Rettie AE, Thummel KE, Paine MF. Clinical assessment of the drug interaction potential of the psychotropic natural product kratom. Clin Pharmacol Ther, online ahead of print, 2023. https://pubmed.ncbi.nlm.nih.gov/36924284.
PMID: 36924284
Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat J, Paine MF, Vandrey R. Assessment of orally administered ?9-tetrahydrocannabinol when coadministered with cannabidiol on ?9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial. JAMA Netw Open, 6(2):e2254752, 2023. https://doi.org/10.1001/jamanetworkopen.2022.54752.
PMID: 36780161
PMCID: PMC9926328
2022
Bansal S, Paine MF, Unadkat JD. Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes. Drug Metab Dispos, 50(4):351-360, 2022. https://doi.org/10.1124/dmd.121.000734
PMID: 35115300
Brogdon HD, McPhee MM, Paine MF, Cox EJ, Burns AG. A case of potential pharmacokinetic kratom-drug interactions resulting in toxicity and subsequent treatment of kratom use disorder with Buprenorphine/Naloxone. J Addict Med, online ahead of print, 2022. https://doi.org/10.1097/adm.0000000000000968
PMID: 35165231
Manwill PK, Flores-Bocanegra L, Khin M, Raja HA, Cech NB, Oberlies NH, Todd DA. Kratom (Mitragyna Speciosa) validation: quantitative analysis of indole and oxindole alkaloids reveals chemotypes of plants and products. Planta Med, 88(9-10):838-857, 2022. https://doi.org/10.1055/a-1795-5876
PMID: 35468648
Piscitelli J, Nikanjam M, Capparelli EV, Blaquera CL, Penzak SR, Nolin TD, Paine MF, Ma JD. Fexofenadine plasma concentrations to estimate systemic exposure in healthy adults using a limited sampling strategy with a population pharmacokinetic approach. Ther Drug Monit, online ahead of print, 2022. https://doi.org/10.1097/ftd.0000000000001052.
PMID: 36645711
Tanna RS, Nguyen JT, Hadi DL, Manwill PK, Flores-Bocanegra L, Layton ME, White JR, Cech NB, Oberlies NH, Rettie AE, Thummel KE, Paine MF. Clinical pharmacokinetic assessment of kratom (Mitragyna Speciosa), a botanical product with opioid-like effects, in healthy adult participants. Pharmaceutics, 14(3):620, 2022. https://doi.org/10.3390/pharmaceutics14030620
PMID: 35335999 PMCID: PMC8950611
Taskar KS, Yang X, Neuhoff S, Patel M, Yoshida K, Paine MF, Brouwer KLR, Chu X, Sugiyama Y, Cook J, Polli JW, Hanna I, Lai Y, Zamek-Gliszczynski M, ITC. Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: an international transporter consortium perspective. Cline Pharmacol Ther, 112(3):573-592, 2022. https://doi.org/10.1002/cpt.2670
PMID: 35612761
2021
Arian CM, Imaoka T, Yang J, Kelly EJ, Thummel KE. Gutsy science: in vitro systems of the human intestine to model oral drug disposition. Pharmacol Ther, 230:107962, 2021. https://doi.org/10.1016/j.pharmthera.2021.107962
PMID: 34478775 PMCID: PMC8821120
Bechtold BJ, Clarke JD. Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy. Expert Opin Drug Metab Toxicol, 17(4):397-412, 2021. https://doi.org/10.1080/17425255.2021.1867105
PMID: 33339463 PMCID: PMC8110027
Clark TN, Houriet J, Vidar WS, Kellogg JK, Todd DA, Cech NB, Linington RG. Interlaboratory comparison of untargeted mass spectrometry data uncovers underlying causes for variability. J Nat Prod, 84(3):824-835, 2021. https://doi.org/10.1021/acs.jnatprod.0c01376
PMID: 33666420 PMCID: PPMC8326878
Cox EJ, Rettie AE, Unadkat JD, Thummel KE, McCune JS, Paine MF. Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: a NaPDI Center recommended approach. Clin Transl Sci, 15(2):322-329, 2021. https://doi.org/10.1111/cts.13172
PMID: 34699676 PMCID: PMC8841492
Cox EJ, Tian DD, Clarke JD, Rettie AR, Unadkat JD, Thummel KE, McCune JS, Paine MF. Modeling pharmacokinetic natural product-drug interactions for decision-making: a NaPDI Center recommended approach. Pharmacol Rev, 73(2):847-859, 2021. https://doi.org/10.1124/pharmrev.120.000106
PMID: 33712517 PMCID: PMC7956993
Lynch KD, Montonye ML, Tian DD, Arman T, Oyanna VO, Bechtold BJ, Graf TN, Oberlies NH, Paine MF, Clarke JD. Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. Phytother Res, Online ahead of print, 2021. https://doi.org/10.1002/ptr.7049
PMID: 33587330 PMCID: PMC8217340
Tanna RS, Tian DD, Cech NB, Oberlies NH, Rettie AE, Thummel KE, Paine MF. Refined prediction of pharmacokinetic kratom-drug interactions: time-dependent inhibition considerations. J Pharmacol Exp Ther, 376(1):64-73, 2021. https://doi.org/10.1124/jpet.120.000270
PMID: 33093187 PMCID: PMC7745086
Zamek-Gliszczynski MJ, Patel M, Yang X, Lutz JD, Chu X, Brouwer KLR, Lai Y, Lee CA, Neuhoff S, Paine MF, Sugiyama Y, Taskar KS, Galetin A. Intestinal P-gp and putative hepatic OATP1B induction: international transporter consortium perspective on drug development implications. Clin Pharmacol Ther, 109(1):55-64, 2021. https://doi.org/10.1002/cpt.1916
PMID: 32460379 PMCID: PMC8020731
Zhou Z, Paine MF, Spindle TR, Huang SM, Zhang L. Cannabis for medical use: clinical pharmacology perspectives on scientific and regulatory challenges. Clin Pharmacol Ther, 111(4):732-735, 2021. https://doi.org/10.1002/cpt.2470
PMID: 34784423 PMCID: PMC9022961
2020
Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Disp, 48(10):1008-1017, 2020. https://doi.org/10.1124/dmd.120.000073
PMID: 32587099 PMCID: PMC7543485
Birer-Williams C, Gufford BT, Chou E, Alilio M, VanAlstine S, Morley RE, McCune JS, Paine MF, Boyce RD. A new data repository for pharmacokinetic natural product-drug interactions: from chemical characterization to clinical studies. Drug Metab Dispos, 48(10):1104-1112, 2020. https://doi.org/10.1124/dmd.120.000054
PMID: 32601103 PMCID: PMC7543481
Flores-Bocanegra L, Raja HA, Graf TN, Augustinovi? M, Wallace ED, Hematian S, Kellogg JJ, Todd DA, Cech NB, Oberlies NH. The chemistry of kratom [Mitragyna speciosa]: updated characterization data and methods to elucidate indole and oxindole alkaloids. J Nat Prod, 83(7):2165-2177, 2020. https://doi.org/10.1021/acs.jnatprod.0c00257
PMID: 32597657 PMCID: PMC7718854
Gaston TE, Mendrick DL, Paine MF, Roe AL, Yeung CK. “Natural” is not synonymous with “safe”: toxicity of natural products alone and in combination with pharmaceutical agents. Regul Toxicol Pharmacol, 113:104642, 2020. https://doi.org/10.1016/j.yrtph.2020.104642
PMID: 32197968 PMCID: PMC7211136
Kellogg JJ, Kvalheim OM, Cech NB. Composite score analysis for unsupervised comparison and network visualization of metabolomics data. Anal Chim Acta, 1095:38-47, 2020. https://doi.org/10.1016/j.aca.2019.10.029
PMID: 31864629 PMCID: PMC6948848
McDonald MG, Tian DD, Thummel KE, Paine MF, Rettie AE. Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects. Drug Metab Dispos, 48(10):1018-1027, 2020. https://doi.org/10.1124/dmd.120.091041
PMID: 32591416 PMCID: PMC754348
Nguyen JT, Tian DD, Tanna RS, Hadi DL, Bansal S, Calamia JC, Arian CM, Shireman LM, Molnhttps://doi.org/10.1002/cpt.2107
PMID: 33174626 PMCID: PMC8058163
Paine MF. Natural products: experimental approaches to elucidate disposition mechanisms and predict pharmacokinetic drug interactions. Drug Metab Dispos, 48(10):956-962, 2020. https://doi.org/10.1124/dmd.120.000182
PMID: 32816868 PMCID: PMC7543467
Todd DA, Kellogg JJ, Wallace ED, Khin M, Flores-bocanegra L, Tanna RS, McIntosh S, Raja HA, Graf TN, Hemby SE, Paine MF, Oberlies NH, Chech NB. Chemical composition and biological effects of kratom (Mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions. Sci Rep, 10: 19158, 2020. https://doi.org/10.1038/s41598-020-76119-w
PMID: 33154449 PMCID: PMC7645423
Wallace ED, Todd DA, Harnly JM, Cech NB, Kellogg JJ. Identification of adulteration in botanical samples with untargeted metabolomics. Anal Bioanal Chem, 412(18):4273-4286, 2020.
https://doi.org/10.1007/s00216-020-02678-6
PMID: 32347364 PMCID: PMC7321857
2019
Birer C, Wright ES. Capturing the Complex Interplay Between Drugs and the Intestinal Microbiome. Clin Pharmacol Ther, 106(3):501-504, 2019. https://doi.org/10.1002/cpt.1505
PMID:31102465 PMCID: PMC7574698
Cox EJ, Maharao N, Patilea-Vrana G, Unadkat JD, Rettie AE, McCune JS, Paine MF. A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther 201:25-38, 2019. https://doi.org/10.1016/j.pharmthera.2019.05.001
PMID: 31071346 PMCID: PMC6708768
Kellogg JJ, Paine MF, McCune JS, Oberlies NH, Cech NB. Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. Nat Prod Rep 36:1196-1221, 2019. https://doi.org/10.1039/c8np00065d
PMID: 30681109 PMCID: PMC6658353
Montonye ML, Tian DD, Arman T, Lynch KD, Hagenbuch B, Paine MF, Clarke JD. A pharmacokinetic natural product-disease-drug interaction: a double hit of silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model. J Pharmacol Exper Ther, 371(2):385-393, 2019. https://doi.org/10.1124/jpet.119.260489
PMID: 31420525 PMCID: PMC6800447
Patilea-Vrana GI, Unadkat JD. Quantifying hepatic enzyme kinetics of (-)-?9-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling. Drug Metab Dispos 47:743-752, 2019. https://doi.org/10.1124/dmd.119.086470
PMID: 31048453 PMCID: PMC6556521
Tian DD, Leonowens C, Cox EJ, González-Pérez V, Frederick KS, Scarlett YV, Fisher MB, Paine MF. Indinavir increases midazolam glucuronidation in humans: identification of an alternate CYP3A inhibitor using an in vitro to in vivo approach. Drug Metab Dispos 47:724-731, 2019. https://doi.org/10.1124/dmd.119.087007
PMID: 31028057 PMCID: PMC6556520
[Figure selected for cover]
Tian DD, Natesan S, White JR J, Paine MF. Effects of common CYP1A2 genotypes and other key factors on intraindividual variation in the caffeine metabolic ratio: an exploratory analysis. Clin Translational Sci 12:39-46, 2019. https://dx.doi.org/10.1111%2Fcts.12598
PMID: 30387917 PMCID: PMC63422440
2018
Boyce RD, Ragueneau-Majlessi I, Yu J, Tay-Sontheimer J, Kinsella C, Chou E, Brochhausen M, Judkins J, Gufford BT, Pinkleton BE, Cooney R, Paine MF, McCune JS. Developing user personas to aid in the design of a user-centered natural product-drug interaction information resource for researchers. AIMA Annu Symp Proc 279-287, 2018.
PMID: 30815066 PMCID: PMC6371317
Caesar LK, Kvalheim OM, Cech NB. Hierarchical cluster analysis of technical replicates to identify interferents in untargeted mass spectrometry metabolomics. Anal Chim Acta 1021: 69–77, 2018. https://doi.org/10.1016/j.aca.2018.03.013
PMID: 29681286 PMCID: PMC5917943
Johnson EJ, González-Peréz V, Lin YS, Unadkat JD, Rettie AE, Shen DD, McCune JS, Paine MF. Selection of priority natural products for evaluation as potential precipitants of natural product-drug interactions: a NaPDI Center recommended approach. Drug Metab Dispos 46:1046-52, 2018. https://doi.org/10.1124/dmd.118.081273
PMID: 29735752 PMCID: PMC6003438
Judkins J, Tay-Sontheimer J, Boyce RD, and Brochhausen M. Extending the DIDEO ontology to include entities from the natural product-drug interaction domain of discourse. J Biomed Semantics 9:15, 2018. https://doi.org/10.1186/s13326-018-0183-z
PMID: 29743102 PMCID: PMC5944177
Paine MF, Roe AL. “Green medicine”: the past, present, and future of botanicals. Clin Pharmacol Ther 104:410-415, 2018. https://doi.org/10.1002/cpt.1168
PMID: 30151884
Paine MF, Shen DD, McCune JS. Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI Center commentary. Drug Metab Dispos 46:1041-5, 2018. https://doi.org/10.1124/dmd.117.079962
PMID: 29735755 PMCID: PMC6003437
Tian DD, Kellogg JJ, Okut N, Oberlies NH, Cech NB, McCune JS, Shen DD, Paine MF. Identification of intestinal UDP-glucuronosyltransferase inhibitors in green tea (Camellia sinensis) using a biochemometric approach: application to raloxifene as a test drug via in vitro to in vivo extrapolation. Drug Metab Dispos 46:552-60, 2018. https://doi.org/10.1124/dmd.117.079491
PMID: 29467215 PMCID: PMC5890833
Wallace ED, Oberlies NH, Cech NB, Kellogg JJ. Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics. Food Chem Toxicol 120:439-447, 2018. https://doi.org/10.1016/j.fct.2018.07.033
PMID: 30031041 PMCID: PMC6434943
2017
Kellogg JJ, Graf TN, Paine MF, McCune JS, Kvalheim OM, Oberlies NH, Cech NB. Comparison of metabolomics approaches for evaluating the variability of complex botanical preparations: green tea (Camellia sinensis) as a case study. J Natr Prod 80:1457-66, 2017. https://doi.org/10.1021/acs.jnatprod.6b01156
PMID: 28453261 PMCID: PMC5469520
Kellogg JJ, Wallace ED, Oberlies NH, Cech NB. Conventional and accelerated-solvent extractions of green tea (Camellia sinensis) for metabolomics-based chemometrics. J Pharm Biomed Anal 145:604-610, 2017. https://doi.org/10.1016/j.jpba.2017.07.027
PMID: 28787673 PMCID: PMC5804813
Poster Presentations
2024
Taneja SB, Li X, Chapin MR, Kane-Gill SL, Boyce RD. Detecting Duplicates in Adverse Event Reports for Cannabis sativa and Mitragyna speciosa (Kratom) Products. Poster presentation, AMIA Annual Symposium 2024.
Taneja, SB, Sivarajkumar, S., Wang, Y., Boyce, RD. Information Extraction from Biomedical Texts using Large Language Models for Natural Product-Drug Interactions. Pacific Symposium on Biocomputing. 1/4/2024. The Big Island of Hawaii, Hawaii, USA.
2023
Abanyie K, Boyce R, Kravchenko O. Validation of Potential Natural Product Drug Interaction Rules Written in HL7 Clinical Quality Language. Poster presentation at: AMIA 2023 Annual Symposium; 2023 Nov 11-15; New Orleans, Louisiana.
Cherel MG: “Clinical pharmacokinetics of a cannabidiol/cannabidiolic acid-rich hemp product.” Oral and poster presentation, 21st Annual ICSB. Oxford, MS. April 24-28, 2023.
Taneja SB. Application of Semantic Knowledge Representation and Natural Language Processing to Identify Pharmacologic Mechanisms. Doctoral Consortium Presentation, International Semantic Web Conference 2023; Athens, Greece; November 6-10, 2023.
Tanna RS: “Clinical assessment of the drug interaction potential of the psychotropic natural product kratom (Mitragyna speciosa).” Oral and poster presentation, ASCPT 2023 Annual Meeting. Atlanta, GA. March 24, 2023.
2022
Bansal S: “Predicting UGT-mediated cannabinoid-drug interactions using static and PBPK models.” Oral and poster presentation, ISSX workshop on Physiologically based Pharmacokinetic Modeling. Virtual Event. June 7-9, 2022.
Kazarov C, Grubic M, Kane-Gill SL, Boyce RD: “Differences in adverse events reporting between natural products versus prescription products in the United States and Canada.” Poster presentation, ISPOR Europe 2022, Vienna, Austria. November 6-9, 2022.
Nguyen JT: “Elucidating mechanisms underlying the goldenseal-midazolam interaction using a modeling and simulation approach.” Oral and poster presentation, 20th Annual ICSB. Oxford, MS. March 28-31, 2022. Awarded 3rd place in poster competition.
Taneja SB, Joachimiak MP, Hegde H, Baumgartner Jr. WA, JH Caufield, Callahan TJ, Mungall CJ, Boyce RD: “Evaluation of named entity recognition systems to improve ontology concept annotation for biomedical knowledge graphs.” Oral and poster presentation, ISMB Bio-ontologies COSI; July 10-14, 2022.
Taneja SB, Ndungu PW, Paine MF, Kane-Gill SL, Boyce RD: “Relation extraction from biomedical literature on pharmacokinetic natural product-drug interactions.” Poster presentation at the 2022 AMIA Informatics Summit. Chicago, Illinois, USA. March 22 – 24, 2022.
Taneja SB, Paine MF, Kane-Gill SL, Boyce RD: “Extending the OMOP standard vocabulary to include botanical natural products.” Poster presentation, Observational Health Data Sciences and Informatics (OHDSI) Symposium; October 14-16, 2022.
Tanna RS: “Clinical assessment of the drug interaction potential of the psychotropic natural product kratom.” Oral and poster presentation, 20th Annual ICSB. Oxford, MS. March 28-31, 2022. Awarded 2nd place in poster competition.
Tanna RS, Nguyen JT, Cech NB, Oberlies NH, Rettie AE, Thummel KE, and Paine MF: “Physiologically based pharmacokinetic models for kratom, a botanical with opioid-like effects, and kratom-drug interactions mediated by CYP3A and CYP2D6.” Poster presentation at the 13th ISSX meeting in Seattle, WA.
2021
Bansal S: “Development and validation of a physiologically-based pharmacokinetic model for cannabidiol in healthy adult, hepatically/renally impaired, and pediatric populations.” Oral and poster presentation, 24th North American ISSX Meeting 2021. Virtual Event. September 13-17, 2021.
Taneja SB, Callahan TJ, Brochhausen M, Paine MF, Kane-Gill SL, Boyce RD: “Designing potential extensions from G-SRS to ChEBI to identify natural product-drug interactions.” Oral and poster presentation, Intelligent Systems for Molecular Biology/European Conference on Computational Biology (ISMB/ECCB) 2021. Virtual Event. July 25-30, 2021. Awarded best poster.
Tanna RS: “Clinical pharmokinetic assessment of kratom (Mitragyna speciosa), a botanical with opioid-like effects.” Oral and poster presentation, Annual College of Pharmacy and Pharmaceutical Sciences Research Day. August 13th, 2021.
Tanna RS: “Clinical Pharmacokinetic assessment of kratom (Mitragyna speciosa), a botanical with opioid-like effects.” Oral and poster presentation, 24th North American ISSX Meeting. Virtual Event. September 13-17, 2021.
2019
Bansal S: “The potential of cannabinoids to precipitate drug interactions.” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 8-12, 2019. Selected for 10-minute talk
Flores-Bocanegra L: “Chemical characterization of alkaloids from kratom (Mitragyna speciosa).” American Society of Pharmacognosy Conference, Madison, WI, July 13-17, 2019.
Nguyen JT: “Assessing the predictive performance of in silico generated binding parameters for various natural product constituents.” 12th international ISSX meeting, Portland, OR, July 28-31, 2019.
Tanna, RS: “The natural product kratom is a potential precipitant of pharmacokinetic interactions with common drugs of abuse.” 12th International ISSX meeting, Portland, OR, July 28-31, 2019.
Tanna RS: “Assessing transporter-mediated goldenseal-drug interactions in healthy volunteers using a transporter cocktail.” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 8-12, 2019. Selected for 10-minute talk
Tanna, RS: “Determining mechanisms underlying the goldenseal midazolam interactions in humans using an in vitro to in vivo approach.” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 7-12, 2019.
Tanna RS: “Determining mechanisms underlying the goldenseal-midazolam interaction in humans using an in vitro to in vivo extrapolation approach.” EB/ASPET Annual Meeting, Orlando, FL, April 6-9, 2019. Selected for 3-minute talk
Tian DD: “Differential effects of silymarin on pitavastatin disposition in rodent models of simple fatty liver versus nonalcoholic steatohepatitis: a natural product-disease-drug interaction.” EB/ASPET Annual Meeting, Orlando, FL, April 6-9, 2019. Selected for 10-minute talk
2018
McCune JS, Tian DD, Hardy PA, Cech NB, Shen DD, Layton ME, White JR, Paine MF: “Green tea decreases raloxifene systemic exposure to below the pre-defined no effect range in healthy volunteers” ASCPT Annual Meeting, Orlando, FL, March 22, 2018.
Wallace ED, Oberlies NH, Cech NB, Kellogg JJ: “Detection of adulteration in goldenseal dietary supplements via mass spectrometry-based metabolomics” International Conference on the Science of Botanicals, Oxford, MS, April 9-12, 2018. [1st Place Poster Award]
2017
Boyce RD, Ragueneau-Majlessi I, Yu J, Sontheimer J, Kinsella K, Brochhausen M, Judkins J, Pinkleton B, Cooney R, Paine MF, McCune JS: “Toward a reliable and interoperable public repository for natural product-drug interaction study data” 2017 Annual Symposium of the American Medical Informatics Association, Washington, DC, November 6, 2017. https://amia2017.zerista.com/poster/member/94177.
Kellogg JJ, Graf TN, Kvalheim OM, Cech NB: “Comparison of MS and NMR metabolomics for evaluation of herbal supplements: a case study with green tea” 5th Annual Practical Applications of NMR in Industry Conference, Hilton Head Island, SC, February 22, 2017.
Kellogg JJ, Wallace ED, Graf TN, Oberlies NH, Cech NB: “Conventional and accelerated-solvent extractions of green tea for metabolomics-based chemometrics” 8th American Council for Medicinally Active Plants Conference, Clemson, SC, June 21, 2017.
Okut N, Kellogg JJ, Tian DD, Paine MF, Oberlies NH, Cech NB: “Biochemometrics to identify drug metabolizing enzyme inhibitors from green tea (Camellia sinensis)” 8th American Council for Medicinally Active Plants Conference, Clemson, SC, June 21, 2017.
Wallace ED, Kellogg JJ, Graf TN, Oberlies NH: “Conventional and accelerated-solvent extractions of green tea for metabolomics-based chemometrics” American Society of Pharmacognosy Annual Meeting, Portland, OR, August 2, 2017.
Wallace ED, Oberlies NH, Cech NB, Kellogg JJ: “Detection of adulteration in goldenseal dietary supplements via mass spectrometry-based metabolomics” Southeast Regional Meeting of the American Chemical Society, Charlotte, NC, November 7-11, 2017.
Tian DD, Kellogg JJ, Oberlies NH, Cech NB, McCune JS, Paine MF: “Identification of intestinal UDP-glucuronosyltransferase inhibitors in green tea using a biochemometric approach” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 11, 2017.
Invited Oral Presentations
2023
Paine MF: “Deciphering mechanisms underlying natural product-drug interactions to improve pharmacotherapy.” 7th Asia Pacific ISSX Meeting, Bangalore, India. Jan 31, 2023
2022
Tanna RS: “Clinical assessment of the drug interaction potential of the psychotropic natural product kratom.” Pacific Northwest Association of Toxicologists 2022 Regional Toxicology Conference. Oct 3, 2022
Tanna RS: “Physiologically based pharmacokinetic models for kratom, a botanical with opioid-like effects, and kratom-drug interactions mediated by CYP3A and CYP2D6.” WSU College of Pharmacy and Pharmaceutical Sciences Industry Advisory Board meeting. Sep 15, 2022
2021
Bansal S: “In vivo evaluation of CYP-mediated cannbinoid-drug interactions in humans.” ASPET/DMDD Webinar. Virtual, September 13-17, 2021
Nguyen J: “Natural products: a safe bet?” WSU College of Pharmacy and Pharmaceutical Sciences Industry Advisory Board meeting. June 10, 2021.
Paine MF: “Natural product-drug interaction research: digging through the intricacies to uncover mechanisms and improve pharmacotherapy.” FDA-ASCPT William Abrams Award lecture, Virtual, May 29, 2021.
Paine MF: “Translational approaches to untangle herb-drug interactions.” 11th International Marbach DDI workshop, Virtual, June 1, 2021.
Paine MF: “Weeding mechanisms of pharmacokinetic marijuana-drug interactions.” ASCPT Annual Meeting, March 9, 2021.
Tanna RS: “Prediction and clinical assessment of the pharmacokinetic drug interaction potential of the psychotropic natural product kratom.” WSU College of Pharmacy and Pharmaceutical Sciences Industry Advisory Board meeting. June 10, 2021.
2019
Cech NB: “A plant by any other name: quality control of botanical natural products for research studies.” Linus Pauling Institute 10th International Conference, Corvallis, OR, August 14, 2019.
Kellogg JJ: “Techniques to identify bioactive constituents from complex mixtures: a biochemometrics approach.” Continuing Education Panel: Complex Mixtures and UVCBs: Analysis, Testing, and Risk Assessment. Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 10, 2019.
Paine MF: “Assessing clinical transporter-mediated herb-drug interactions using a cocktail approach.” 4th International Ling-nan DMPK Forum, Guangzhao, China, November 24, 2019.
Paine MF: “Causative ingredients and mechanisms underlying interactions between prescription and non-prescription medications and natural products.” Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 10, 2019.
Paine MF: “Clinical natural product-drug interactions: harvesting precipitants and mechanisms.” 22nd International Conference on Drug-Drug Interactions, Seattle, WA, June 20, 2019.
Paine MF: “Natural product-drug interaction research: cultivating best practices.” Linus Pauling Institute 10th International Conference, Corvallis, OR, August 14, 2019.
Paine MF: “Translational approaches to address potential clinically significant enteric xenobiotic-drug interactions: case study involving the herbal product green tea.” EB/ASPET Annual Meeting, Orlando, FL, April 9, 2019.
Paine MF: “Translational approaches to assess pharmacokinetic herb-drug Interactions.” 12th International ISSX Meeting, Portland, OR, July 29, 2019.
Paine MF: “Untangling mechanisms underlying natural product-drug interactions.” International Conference on Cytochrome P450, Brisbane, Australia, June 27, 2019.
Thummel KE: “Intestinal drug metabolizing enzymes and transporters: a review.” Symposium: Enteric Drug Metabolism and Drug-Drug Interactions. EB/ASPET Annual Meeting, Orlando, FL, April 9, 2019.
Thummel KE: Opening Remarks: “DDI hot topics.” 22nd International Conference on Drug-Drug Interactions, Seattle, WA, June 20, 2019.
Unadkat JD: “Cannabinoid-drug interactions: getting into the weeds.” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 9, 2019.
2018
Cech NB: “Untargeted metabolomics for assessing similarity, detecting adulteration, and identifying bioactive constituents in botanical dietary supplements.” National Institute of Environmental and Health Sciences, Durham, NC, September 12, 2018.
Cech NB: “Untargeted metabolomics for assessing similarity, detecting adulteration, and identifying bioactive constituents in botanical dietary supplements.” Procter and Gamble, Cincinnati, OH, September 23, 2018.
Cech NB: “Untargeted metabolomics for selection of botanical natural products prior to in vitro or in vivo evaluation: the role of reference materials.” International Conference on the Science of Botanicals, Oxford, MS, April 9-12, 2018.
Clarke JC: “Overlapping hits on drug disposition: special populations within special populations.” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 12, 2018.
Kellogg JJ: “Workshop: practical implementation of metabolomics for the study of botanicals.” International Conference on the Science of Botanicals, Oxford, MS, April 9-12, 2018.
Paine MF: “Assessing a pharmacokinetic green tea-drug interaction from bench to bedsides.” FDA, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, MD, June 5, 2018.
Paine MF: “Assessing pharmacokinetic natural product-drug interactions: challenges and opportunities.” Delaware Valley Drug Metabolism Discussion Group – Rozman Memorial Symposium: Contributions of Women Scientists to Drug Metabolism, Drug Transporter, and Pharmacokinetics Research, Philadelphia, PA, June 14, 2018.
Paine MF: “Evaluating potential cannabis-drug interactions.” Cannabis Research Retreat, University of Washington, Seattle, WA, October 3, 2018.
Paine MF: “Natural product-drug interactions: progress towards recommended approaches.” FDA, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, MD, May 25, 2018.
2017
Cech NB: “New approaches for identifying the biologically active components of botanical natural products.” 2nd Annual Joint CNPHARS-ASPET Meeting on Pharmacology, Hangzhou, China, November 3, 2017.
Kellogg JJ: “Comparative analytical approaches to metabolomic studies of herbal supplements and natural products.” Central North Carolina Section of the American Chemical Society, Greensboro, NC, October 23, 2017.
Kellogg JJ, Kvalheim OM, Oberlies NH, Cech NB: “Multivariate correlation for botanical supplements and assigning quantifiable similarity.” 254th American Chemical Society National Meeting, Washington, DC, August 22, 2017.
Kellogg JJ, Kvalheim OM, Oberlies NH, Cech NB: “Studies in similarity: metabolomics-based multivariate correlation for comparison of natural products.” American Society of Pharmacognosy Annual Meeting, Portland, OR, July 31, 2017.
Kellogg JJ, Tian DD, Oberlies NH, Paine MF, Cech NB: “Biochemometric analysis identifies drug metabolizing enzyme inhibitors from green tea (Camellia sinensis).” 2017 Southeast Regional Meeting of the American Chemical Society, Charlotte, NC November 7-11, 2017.
Paine MF: “A systematic approach to select and evaluate natural products as precipitants of pharmacokinetic natural product-drug interactions.” 2nd Annual Joint CNPHARS-ASPET Meeting on Pharmacology, Hangzhou, China, November 3, 2017.
Paine MF: “Identification of natural products as precipitants of clinical drug interactions: challenges and opportunities.” Gordon Research Conference on Drug Metabolism, Holderness, NH, July 11, 2017.
Paine MF: “Intestinal UGTs as targets for pharmacokinetic natural product-drug interactions.” 254th American Chemical Society National Meeting, Washington, DC, August 21, 2017.
2016
Cech NB: “Integrating biological and chemical datasets to identify active constituents of natural product mixtures.” National Toxicology Program/ NIEHS Workshop, Bethesda, MD, April 26, 2016.
Paine MF: “Natural product-drug interaction research: the roadmap to best practices.” Council for Responsible Nutrition Day of Science, Dana Point, CA, October 26, 2016.
Thummel KE: “New frontiers for the study and prediction of drug-drug interactions.” 19th International Conference on Drug-Drug Interactions, Seattle, WA, June 20, 2016.
Webinar
2021
Paine MF: “Uncovering transporter-mediated natural product-drug interactions using translational tools.” International Society for the Study of Xenobiotics Webinar, Virtual, June 8, 2021.
Symposia
2019
Gordon Research Conference on Drug Metabolism, Holderness, NH, July 9, 2019: “Translational Approaches to Untangle Xenobiotic-Drug Interaction Mechanisms and Improve Pharmacotherapy”
Chair: Mary Paine
- Dr. Elaine Tseng (Pfizer) “Optimizing in vitro tools for successful translation of time-dependent inhibitors”
- Dr. John Harrelson (Pacific Univ) “Variety is the spice of life: pre-clinical approaches to evaluate mechanisms of cinnamaldehyde-drug interactions”
- Dr. Jash Unadkat (UW and NaPDI Center co-investigator) “Cannabinoid-drug interactions: getting into the weeds”
- Dr. Janne Backman (Univ of Helsinki) “Clinical approaches to untangle complex drug-drug interaction mechanisms”
EB/ASPET, Orlando, FL, April 6, 2019: “Natural product-drug interactions: complex mechanisms and public health impact”
Co-chairs: Mary Paine and Amy Roe
- Dr. Amy Roe, co-chair (Procter & Gamble and EAP member): “Botanical-drug interaction assessment: a critical tier in a systematic approach to botanical safety”
- Dr. Chuan Li (Shanghai Institute of Materia Medica): “Chinese herbal medicines as objects or precipitants of natural product-drug interactions”
- Dr. Brandon Gufford (Covance, Inc. and NaPDI Center collaborator): “Sharing is caring: user-centered development of a natural product-drug interaction information portal”
- Dr. Dan-Dan Tian (WSU and NaPDI Center trainee): “Differential effects of silymarin on pitavastatin disposition in rodent models of simple fatty liver versus nonalcoholic steatohepatitis: a natural product-disease-drug interaction”
- Dr. Bill Gurley (University of Arkansas for Medical Sciences): “‘…Not intended to diagnose, treat, cure or prevent any disease’: 25 years of botanical dietary supplement usage and the lessons learned”
Other
Conference paper
Boyce RD, Ragueneau-Majlessi I, Yu J, Tay-Sontheimer J, Kinsella C, Chou E, Brochhausen M, Judkins J, Gufford BT, Pinkleton BE, Cooney R, Paine MF, McCune JS. Developing user personas to aid in the design of a user-centered natural product-drug interaction information resource for researchers. AMIA Annual Symposium proceedings. AMIA Symposium. 2018:279-287.
Judkins J, Tay-Sontheimer J, Boyce RD, and Brochhausen M: “Extending the DIDEO ontology to include entities from the natural product drug interaction domain of discourse” 6th International Workshop on Vaccine and Drug Ontology Studies, International Conference on Biomedical Ontology, Newcastle University, UK, September 13-15, 2017.
Webinar
Paine MF: “Natural product-drug interactions: case studies from the NaPDI Center” SOLVO Biotechnology, October 25, 2017.
Themed issues
Drug Metabolism and Disposition
Guest editor: Mary Paine
Cover art (left) by Mary Paine’s student, Sabrina Judson, and co-designed with Mary Paine
October 2020
Clinical Pharmacy & Therapeutics
Co-editors: Mary Paine and Amy Roe
September 2018